Beijing Hotgen Biotech Co., Ltd. (688068.SH) Announces Positive Preliminary Results from Phase Ib Clinical Trial of SGC001

Stock News10-22

Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its investee company, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (referred to as "Shunjing Biopharma"), reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001 injection. The initial efficacy results indicate that in patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) in China, SGC001 demonstrated a favorable trend in myocardial protection in both the 600mg and 900mg dosage groups compared to the placebo. This is evidenced by a decrease in the percentage of myocardial infarction area (IS%), along with a shorter time required for high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels. Compared to the placebo group, there was a trend of increased efficacy with higher doses, with the median percentage reduction in myocardial infarction area of 20.5% and 38.1%, respectively, in the mid to high dosage groups. The project will continue to follow the clinical trial protocol for further clinical activities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199372721?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 16:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199372721","market":"us","top_or_hot":-1,"title":"Beijing Hotgen Biotech Co., Ltd. (688068.SH) Announces Positive Preliminary Results from Phase Ib Clinical Trial of SGC001","media":"Stock News","content":"<p>Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its investee company, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (referred to as \"Shunjing Biopharma\"), reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001 injection. The initial efficacy results indicate that in patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) in China, SGC001 demonstrated a favorable trend in myocardial protection in both the 600mg and 900mg dosage groups compared to the placebo. This is evidenced by a decrease in the percentage of myocardial infarction area (IS%), along with a shorter time required for high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels. Compared to the placebo group, there was a trend of increased efficacy with higher doses, with the median percentage reduction in myocardial infarction area of 20.5% and 38.1%, respectively, in the mid to high dosage groups. The project will continue to follow the clinical trial protocol for further clinical activities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Hotgen Biotech Co., Ltd. (688068.SH) Announces Positive Preliminary Results from Phase Ib Clinical Trial of SGC001</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Hotgen Biotech Co., Ltd. (688068.SH) Announces Positive Preliminary Results from Phase Ib Clinical Trial of SGC001\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-22 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its investee company, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (referred to as \"Shunjing Biopharma\"), reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001 injection. The initial efficacy results indicate that in patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) in China, SGC001 demonstrated a favorable trend in myocardial protection in both the 600mg and 900mg dosage groups compared to the placebo. This is evidenced by a decrease in the percentage of myocardial infarction area (IS%), along with a shorter time required for high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels. Compared to the placebo group, there was a trend of increased efficacy with higher doses, with the median percentage reduction in myocardial infarction area of 20.5% and 38.1%, respectively, in the mid to high dosage groups. The project will continue to follow the clinical trial protocol for further clinical activities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1199372721","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199372721","pubTimestamp":1761120733,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its investee company, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (referred to as \"Shunjing Biopharma\"), reported positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","688068":"热景生物","BK0239":"医药制造","06978":"永泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"北京霍特根生物技术股份有限公司（688068.SH）公布SGC001 Ib期临床试验积极初步结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"688068":1,"06978":1},"content_text":"Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its investee company, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (referred to as \"Shunjing Biopharma\"), reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001 injection. The initial efficacy results indicate that in patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) in China, SGC001 demonstrated a favorable trend in myocardial protection in both the 600mg and 900mg dosage groups compared to the placebo. This is evidenced by a decrease in the percentage of myocardial infarction area (IS%), along with a shorter time required for high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels. Compared to the placebo group, there was a trend of increased efficacy with higher doses, with the median percentage reduction in myocardial infarction area of 20.5% and 38.1%, respectively, in the mid to high dosage groups. The project will continue to follow the clinical trial protocol for further clinical activities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199372721","isCrawlerRequest":true}